Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK1 | O14757 | 3/20 | 0.49 |
| ▸ | CDK1 | P06493 | 1/20 | 0.49 |
| ▸ | CDK4 | P11802 | 1/20 | 0.49 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.49 |
| ▸ | CCND1 | P24385 | 1/20 | 0.49 |
| ▸ | CDK2 | P24941 | 1/20 | 0.49 |
| ▸ | CCND3 | P30281 | 1/20 | 0.49 |
| ▸ | KDR | P35968 | 13/20 | 0.47 |
| ▸ | AURKA | O14965 | 4/20 | 0.43 |
| ▸ | CSF1R | P07333 | 1/20 | 0.42 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.42 |
| ▸ | KIT | P10721 | 1/20 | 0.42 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.42 |
| ▸ | AURKB | Q96GD4 | 3/20 | 0.41 |
| ▸ | FGFR1 | P11362 | 4/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6428457 | 0.89 | KDR (0.46) | CHEK1CDK4KDRAURKACSF1R | |
| SCHEMBL5030146 | 0.88 | KDR (0.46) | CHEK1CDK1CDK4CCNA2CCND1 | |
| SCHEMBL6427685 | 0.88 | CHEK1 (0.47) | CHEK1CDK1CDK4CCNA2CCND1 | |
| SCHEMBL6427851 | 0.88 | CHEK1 (0.45) | CHEK1CDK1CDK4CCNA2CCND1 | |
| SCHEMBL6428370 | 0.87 | KDR (0.45) | CHEK1CDK1CDK4CCNA2CCND1 | |
| SCHEMBL5034375 | 0.86 | AURKA (0.44) | CHEK1CDK1CDK4CCNA2CCND1 | |
| SCHEMBL5034286 | 0.86 | AURKA (0.44) | CHEK1CDK1CDK4CCNA2CCND1 | |
| SCHEMBL4150149 | 0.85 | CHEK1 (0.51) | CHEK1CDK1CDK4CCNA2CCND1 | |
| SCHEMBL4150153 | 0.85 | CHEK1 (0.51) | CHEK1CDK1CDK4CCNA2CCND1 | |
| SCHEMBL13927666 | 0.83 | GSK3B (0.52) | CHEK1CDK1CDK4CCNA2CCND1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050261339-A1 | Pyrazole compound and medicinal composition containing the same | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2005-11-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050261339-A1 | Pyrazole compound and medicinal composition containing the same | CNKSR1, NR3C2, CSNK2B | CHEK1 657/4885CDK1 180/4885CDK4 260/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.